Synthetic biotechnology company Amyris, Inc. (NASDAQ: AMRS) recently revealed that it has entered into an agreement to acquire menopause symptoms treatment company, MenoLabs, LLC. The financial terms of the deal have been kept under wraps. Following the news, shares of the company jumped 10.1% on Monday. The stock, however, pared its gains slightly to close at $4.58 in the extended trading session. Strategic Impact With menopause symptoms affecting almost 25 million women each year, the market is a growing one and is expected to reach roughly $23 billion by 2028.
https://www.tipranks.com/news/amyris-to-acquire-menolabs-shares-pop-10-1?utm_source=advfn.com&utm_medium=referral
Amyris (NASDAQ:AMRS)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Amyris Charts.
Amyris (NASDAQ:AMRS)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Amyris Charts.